Klaus J. Busam

TL;DR: The genetic alterations identified in melanoma at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.

TL;DR: Imatinib may offer an immediate therapeutic benefit for a significant proportion of the global melanoma burden because the majority of the KIT mutations found in melanoma also occur in imatinib-responsive cancers of other types.

TL;DR: A multiple instance learning-based deep learning system that uses only the reported diagnoses as labels for training, thereby avoiding expensive and time-consuming pixel-wise manual annotations, and has the ability to train accurate classification models at unprecedented scale.

TL;DR: Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development of uveal melanoma.

TL;DR: Among patients with advanced melanoma harboring KIT alterations, treatment with imatinib mesylate results in significant clinical responses in a subset of patients, indicating positive selection for the mutated allele.